NeOnc Technologies Holdings Receives FDA Authorization to Proceed with Phase 1/2 Trials of NEO212 for Primary Brain Tumors and for Brain Metastasis in Combination with Standard of Care Therapy
27 juin 2023 11h00 HE
|
NeOnc Technologies Holdings, Inc.
U.S. FDA authorizes NeOnc to initiate Phase 1/2 clinical trials of NEO212.Clinical trials to evaluate NEO212 as a single agent for patients with primary brain tumors or uncontrolled brain...
NeOnc Technologies Formalizes Exclusive Global IP Licensing Agreement with USC for Enhanced Method of Delivering Novel Pharma Therapeutics to the Brain
24 avr. 2023 11h00 HE
|
NeOnc Technologies Holdings, Inc.
LOS ANGELES, April 24, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology company, has formally secured exclusive worldwide rights from the University...
NeOnc Technologies Appoints Sidra Medicine CEO and Forbes Top 100 Healthcare Leader, Dr. Iyabo Tinubu-Karch, to Scientific Advisory Board
18 avr. 2023 09h15 HE
|
NeOnc Technologies Holdings, Inc.
LOS ANGELES, April 18, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology company, has appointed Dr. Iyabo Tinubu-Karch to its scientific advisory...
NeOnc Technologies CEO, Thomas Chen, MD, Ph.D., Awarded American Health Council’s ‘Best in Medicine’
04 avr. 2023 14h00 HE
|
NeOnc Technologies Holdings, Inc.
LOS ANGELES and CHICAGO and LONDON, April 04, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings Inc., a clinical stage medical biotechnology company, announced that its CEO, Thomas Chen, MD,...
NeOnc Technologies Engages Anova Enterprises to Pursue Pediatric Brain Tumor Indication and FDA Fast-Track Status for NEO100®
06 mars 2023 08h00 HE
|
NeOnc Technologies Holdings, Inc.
Anova Enterprises, a clinical research organization, to prepare FDA Fast Track and Rare Pediatric Designation application for NEO100® for Pediatric High-Grade Gliomas (pHGGS) brain tumors.AnovaOS™...
NeOnc Technologies Completes $10.0 Million Equity Funding Round
08 févr. 2023 11h00 HE
|
NeOnc Technologies Holdings, Inc
LOS ANGELES, Feb. 08, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology company, has completed a $10.0 million equity funding round at a post-money...